Variation in the COX-2 gene may modify the effect of alendronate on vertebral fracture prevention

European Journal of Inflammation

Volumn 8, Issue 3, 2010, Pages 143-149

  Hossein nezhad, Arash ^a   Mirzaei, K ^a   Birami Jamal, F ^b   Mirfakhraei, R ^b   Sedighi, N ^c  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b National institute of genetic Engineering and Biotechnology   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Alendronate; Bone mineral density; Bone turn over; COX 2; Inflammatory factors; Vertebral fracture

Indexed keywords

ALENDRONIC ACID; CALCIUM; CYCLOOXYGENASE 2; INTERLEUKIN 1; INTERLEUKIN 6; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; PARATHYROID HORMONE; TUMOR NECROSIS FACTOR ALPHA; VITAMIN D;

ADULT; ALLELE; ARTICLE; BONE DENSITY; DRUG EFFICACY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOSITY; HIP; HUMAN; HUMAN TISSUE; INTERVENTION STUDY; LABORATORY TEST; MAJOR CLINICAL STUDY; PARATHYROID HORMONE BLOOD LEVEL; POLYMERASE CHAIN REACTION; POSTMENOPAUSE OSTEOPOROSIS; RADIOGRAPHY; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; SPINE; VERTEBRA FRACTURE;

EID: 80755185587     PISSN: 1721727X     EISSN: None     Source Type: Journal    
DOI: 10.1177/1721727X1000800302     Document Type: Article

References (25)

1. Saghafi H, Hossein-nezhad A, Sedighi N, Tofighi P, Soltani A, Larijani B, Hafezi R. Osteoimmunological insight into vertebral fractures in osteoporosis. Iranian J Pub. Health 2008; 1(S):7-15.
2. Simon AM, Manigrasso MB, O'Connor JP. Cyclooxygenase 2 function is essential for bone fracture healing. J Bone Miner Res 2002; 17:963-76. (Pubitemid 34535133)
3. Kawaguchi H, Pilbeam CC, Harrison JR, Raisz LG. The role of prostaglandins in the regulation of bone metabolism. Clin Orthop 1995; 313:36-46.
4. Wadleigh DJ, Herschman HR. Transcriptional regulation of the cyclooxygenase-2 gene by diverse ligands in murine osteoblasts. Biochem Biophys Res Commun 1999; 264:865-70.
5. Wang LY, Wang HY, Ouyang J, Yu L, Chen B, Qin JQ, Qiu XZ. Low concentration of lipopolysaccharide acts on MC3T3-E1 osteoblasts and induces proliferation via the COX-2-independent NFB pathway. Cell Biochem Funct 2009; 27:238-42.
6. Zhang X, Schwarz EM, Young DA, Puzas JE, Rosier RN, O'Keefe J. Cyclooxygenase-2 regulates mesenchymal cell differentiation into the osteoblast lineage and is critically involved in bone repair. J Clin Invest 2002; 109:1405-15. (Pubitemid 34596166)
7. Poole EM, Bigler J, Whitton J, Sibert JG, Potter JD, Ulrich CM. Prostacyclin synthase and arachidonate 5-lipoxygenase polymorphisms and risk of colorectal polyps. Cancer Epidemiol Biomarkers Prev 2006; 15:502-8.
8. Dekel S, Lenthall G, Francis MJ. Release of prostaglandins from bone and muscle after tibial fracture. J Bone Joint Surg Am 1981; 163:185-9. (Pubitemid 11098763)
9. Weinstein RS, Roberson PK, Manolagas SC. Giant osteoclast formation and long-term oral bisphosphonate therapy. N Engl J Med 2009; 360:53-62.
10. Allen MR, Iwata K, Phipps R, Burr DB. Alterations in canine vertebral bone turnover, microdamage accumulation, and biomechanical properties following 1-year treatment with clinical treatment doses of risedronate or alendronate. Bone 2006; 39:872-79. (Pubitemid 44311727)
11. Allen MR, Burr DB. Three years of alendronate treatment results in similar levels of vertebral microdamage as after one year of treatment. J Bone Miner Res 2007; 22:1759-65. (Pubitemid 351235142)
12. Schaffler MB, Choi K, Milgrom C. Aging and matrix microdamage accumulation in human compact bone. Bone 1995; 17:521-5. (Pubitemid 26017572)
13. Sanders JM, Ghosh S, Chan JM, et al. Quantitative structure-activity relationships for gammadelta T cell activation by bisphosphonates. J Med Chem 2004; 47:375-84. (Pubitemid 38057881)
14. Saghafi H, Hossein-nezhad A, Sedighi N, Tofighi P, Soltani A, Larijani B, Hafezi R. Osteoimmunological Insight into vertebral fractures in osteoporosis. Iranian J Publ Health 2008; 1(S):7-15.
15. Mirzaei K, Hossein-nezhad A, Hosseinzadeh-Attar M, Najmafshar A, Jafari N, Rahmani M, Larijani B. Relationship between genotype and serum levels of adipokines and bone mineral density in type 2 diabetes mellitus patients. Iranian J Diabetes Lipid Disorders 2009; 8:77-86.
16. Tofighi P, Hossein-Nezhad A, SedighiN, Maghbooli ZH, Larijani B.Vertebral geometry parameters can predict fractures. Iranian J Pub Health 2007; 36:14-23.
17. Biramijamal F, Basatvat S, Hossein-Nezhad A, Soltani MS, Akbari Noghabi K, Irvanloo G, Shamimi K. Association of COX-2 promoter polymorphism with gastrointestinal tract cancer in Iran. Biochem Genet 2010; [Epub ahead of print].
18. MacLean C, Newberry S, Maglione M, et al. Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med 2008; 148:197-213. (Pubitemid 351665507)
19. Sitarz R, Leguit RJ, de Leng WW, Polak M, Morsink FM, Bakker O, Maciejewski R, Offerhaus GJ, Milne AN. The COX-2 promoter polymorphism -765 G>C is associated with early-onset, conventional and stump gastric cancers. Mod Patho 2008; 121:685-90. (Pubitemid 351744833)
20. Lerner UH. Inflammation-induced bone remodeling in periodontal disease and the influence of postmenopausal osteoporosis. J Dent Res 2006; 85:596-607. (Pubitemid 44085948)
21. Hossein-Nezhad A, Mirzaei K, Maghbooli Z, Najmafshar A, Larijani B. The influence of folic acid supplementation on maternal and fetal bone turnover. J Bone Miner Metab 2010. [Epub ahead of print]
22. Saghafi H, Hossein-nezhad A, Rahmani M, Larijani B. Relationship between lipid profile and bone turnover in pre and postmenopausal women. Iranian J Pub Health 2008; S1:23-29.
23. Hossein-nezhad A, Ahangari G, Larijani B. Evaluating of VDR gene variation and its interaction with immune regulatory molecules in osteoporosis. Iranian J Pub Health 2009; 38:27-36.
24. Wei S, Kitaura H, Zhou P, Ross FP, Teitelbaum SL. IL-1 mediates TNF-induced osteoclastogenesis. J Clin Invest 2005; 115:282-90. (Pubitemid 40385470)
25. Lam J, Takeshita S, Barker JE, Kanagawa O, Ross FP, Teitelbaum SL. TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest 2000; 106:1481-8. (Pubitemid 32038586)